Señales en vivo de SIGHT.PA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 abr 2024 @ 11:35):

Stats
Volumen de hoy	83 796.00
Volumen promedio	153 930
Capitalización de mercado	30.82M
EPS	€0 ( 2024-03-26 )
Próxima fecha de ganancias	( €0 ) 2024-05-29
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.730
ATR14	€0.00800 (2.07%)

Gensight Biologics SA Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gensight Biologics SA Finanzas

Annual	2023
Ingresos:	€1.27M
Beneficio Bruto:	€3.00M (236.78 %)
EPS:	€-0.540

FY	2023
Ingresos:	€1.27M
Beneficio Bruto:	€3.00M (236.78 %)
EPS:	€-0.540

FY	2022
Ingresos:	€2.58M
Beneficio Bruto:	€2.58M (100.00 %)
EPS:	€-0.600

FY	2021
Ingresos:	€5.28M
Beneficio Bruto:	€0.00 (0.00 %)
EPS:	€-0.630

Financial Reports:

No articles found.

Gensight Biologics SA

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.